Evidence map›Paper›PMID 37763290›Full record

ReviewLife (Basel, Switzerland)2023

Africa (COVID-19) Vaccine Technology Transfer: Where Are We?

Elijah Kolawole Oladipo, Seun Elijah Olufemi, Taiwo Ooreoluwa Ojo, Daniel Adewole Adediran, Akindele Felix Idowu, Usman Abiodun Idowu, Helen Onyeaka

Abstract readReview
In one paragraph

Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elijah Kolawole OladipoDepartment of Microbiology, Laboratory of Molecular Biology, Bioinformatics and Immunology, Adeleke University, P.M.B. 250, Ede 232104, Osun State, Nigeria.ORCID 0000-0002-9646-5122
Seun Elijah OlufemiGenomics Unit, Helix Biogen Institute, Ogbomoso 212102, Oyo State, Nigeria.ORCID 0000-0002-8292-2345
Taiwo Ooreoluwa OjoGenomics Unit, Helix Biogen Institute, Ogbomoso 212102, Oyo State, Nigeria.
Daniel Adewole AdediranGenomics Unit, Helix Biogen Institute, Ogbomoso 212102, Oyo State, Nigeria.ORCID 0000-0003-2907-3783
Akindele Felix IdowuGenomics Unit, Helix Biogen Institute, Ogbomoso 212102, Oyo State, Nigeria.
Usman Abiodun IdowuGenomics Unit, Helix Biogen Institute, Ogbomoso 212102, Oyo State, Nigeria.ORCID 0000-0003-4845-7571
Helen OnyeakaSchool of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham B12 2TT, UK.ORCID 0000-0003-3846-847X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rampant spread of the COVID-19 infection poses a grave and formidable challenge to global healthcare, with particular concern to the inhabitants of the African continent. In response to these pressing concerns, different strategies have been employed to combat the emergence of this insidious disease, encompassing crucial measures such as physical distancing, the utilization of face masks, meticulous hand hygiene, and widespread vaccination campaigns. Nevertheless, the economic realities faced by numerous African nations, characterized by their classification as "low-income countries (LICs)", present a formidable barrier to accessing and distributing approved vaccines to their populations. Moreover, it is essential to discuss the hesitancy of the European Union (EU) in releasing intellectual property rights associated with the transfer of vaccine technology to Africa. While the EU has been a key player in global efforts to combat the pandemic, there has been reluctance in sharing valuable knowledge and resources with African countries. This hesitancy raises concerns about equitable vaccine access and the potential for a prolonged health crisis in Africa. This review underscores the urgent imperative and need of establishing localized vaccine development and production facilities within Africa, necessitating the active involvement of governments and collaborative partnerships to achieve this crucial objective. Furthermore, this review advocates for the exploration of viable avenues for the transfer of vaccine technology as a means to facilitate equitable vaccine access across the African continent and also the cruciality and the need for the EU to reconsider its stance and actively engage in transferring vaccine technology to Africa through sharing intellectual property. The EU can contribute to the establishment of localized vaccine production facilities on the continent, which will not only increase vaccine availability but also promote self-sufficiency and resilience in the face of future health emergencies.

Indexed as

AfricaCOVID-19technologytransfervaccine

Identifiers

PMID37763290
PMCPMC10532490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.